Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients

Journal of Medical Virology

Volumn 87, Issue 5, 2015, Pages 836-844

  Mengelle, Catherine ^a   Rostaing, Lionel ^b   Weclawiak, Hugo ^b   Rossignol, Cécile ^a   Kamar, Nassim ^b   Izopet, Jacques ^a,c  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

^c INSERM   (France)

Author keywords

CMV DNAemia; CMV infection prevention strategies; Ganciclovir; Valganciclovir

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; COLD ISCHEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONITORING; NONHUMAN; SURVIVAL RATE; VIRUS LOAD; VIRUS REACTIVATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; SURVIVAL; TIME; VIREMIA; YOUNG ADULT;

CYTOMEGALOVIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANT RECIPIENTS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84925157826     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23964     Document Type: Article

References (44)

1. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Toz H, Dittmer I, Montejo M, Hartmann A. 2009. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9:1205-1213.
2. Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Peralvarez M, Rolando N, Harber M, Jones G, O'Riordan A, Burroughs AK, Thorburn D, O'Beirne J, Milne RS, Emery VC, Griffiths PD. 2012. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 12:2457-2464.
3. Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV. 1997. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 64:66-73.
4. Bodro M, Sabe N, Llado L, Baliellas C, Niubo J, Castellote J, Fabregat J, Rafecas A, Carratala J. 2012. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 18:1093-1099.
5. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A. 2009. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 14:697-704.
6. Boivin G, Goyette N, Farhan M, Ives J, Elston R. 2012. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 53:208-213.
7. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. 2011. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 11:2181-2189.
8. Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, Lafon ME, Boyer B, Alain S, Garrigue I, Merville P. 2012. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 12:202-209.
9. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. 1997. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729-1733.
10. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. 2013. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 85:893-898.
11. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. 2005. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 365:2105-2115.
12. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC. 2007. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD005129.
13. Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. 2013. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD003774.
14. Humar A. 2006. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 82:S9-S14.
15. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. 2005. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143:870-880.
16. Kim JM, Kim SJ, Joh JW, Kwon CH, Song S, Shin M, Moon JI, Kim GS, Hong SH, Lee SK. 2011. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transpl 17:446-455.
17. Lautenschlager I, Loginov R, Makisalo H, Hockerstedt K. 2013. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients. J Clin Virol 57:50-53.
18. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. 2008. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 8:158-161.
19. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649.
20. Ljungman P. 1995. Workshop on CMVdisease definitions, clinical severity scores and new syndromes. Scand J Infect Dis 99:87.
21. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. 2013. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 56:817-824.
22. Mengelle C, Sandres-Saune K, Pasquier C, Rostaing L, Mansuy JM, Marty M, Da Silva I, Attal M, Massip P, Izopet J. 2003. Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J Clin Microbiol 41:3840-3845.
23. Muller V, Perrakis A, Meyer J, Fortsch T, Korn K, Croner RS, Yedibela S, Hohenberger W, Schellerer VS. 2012. The value of pre-emptive therapy for cytomegalovirus after liver transplantation. Transplant Proc 44:1357-1361.
24. Onor IO, Todd SB, Meredith E, Perez SD, Mehta AK, Marshall Lyon G, Knechtle SJ, Hanish SI, 2013. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int 26:592-600.
25. Opelz G, Dohler B, Ruhenstroth A. 2004. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:928-936.
26. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. 2004. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611-620.
27. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ, Wiesner RH. 2002. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial. J Infect Dis 185:854-860.
28. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, Espy MJ, Kremers W, Wilson JA, Groettum C, Wiesner R, Paya CV. 2002. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 35:974-981.
29. Razonable RR, Paya CV. 2003. Herpesvirus infections in transplant recipients: Current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10:60-65.
30. Razonable RR, Emery VC. 2004. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 11:77-86.
31. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O. 2012. Review article: Use of induction therapy in liver transplantation. Transplant Rev (Orlando) 26:246-260.
32. Schnitzler MA, Lowell JA, Hmiel SP, Hardinger KL, Liapis H, Ceriotti CS, Brennan DC. 2003. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 14:780-785.
33. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA. 2009. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 15:963-967.
34. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. 2000. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial. Transplantation 70:717-722.
35. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. 2005a. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 79:85-90.
36. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. 2005b Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 11:700-704.
37. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. 2005c Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 79:1428-1434.
38. Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV. 2008. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 14:240-244.
39. Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR. 2005. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 11:1597-1602.
40. Small LN, Lau J, Snydman DR. 2006. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43:869-880.
41. Stahl JE, Kreke JE, Malek FA, Schaefer AJ, Vacanti J. 2008. Consequences of cold-ischemia time on primary nonfunction and patient and graft survival in liver transplantation: A meta-analysis. PLoS ONE 3:e2468.
42. Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A. 2012. Cytomegalovirus infection: Its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: A single-center experience. Liver Transpl 18:1448-1455.
43. Weigand K, Schnitzler P, Schmidt J, Chahoud F, Gotthardt D, Schemmer P, Stremmel W, Sauer P. 2010. Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis. Transplant Proc 42:2634-2641.
44. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. 2012. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 93:61-68.